Healthcare - Biotechnology - NASDAQ - GB
$ 1.05
-1.87 %
$ 43.1 M
Market Cap
-0.66
P/E
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.[ Read More ]
The intrinsic value of one ACHL stock under the base case scenario is HIDDEN Compared to the current market price of 1.05 USD, Achilles Therapeutics plc is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ACHL
FINANCIALS
0
REVENUE
-75.3 M
OPERATING INCOME
-69.9 M
NET INCOME
-48.4 M
OPERATING CASH FLOW
-1.1 M
INVESTING CASH FLOW
9 K
FINANCING CASH FLOW
0
REVENUE
-17.8 M
OPERATING INCOME
-16.4 K
NET INCOME
-17.3 M
OPERATING CASH FLOW
-36
INVESTING CASH FLOW
4.42
FINANCING CASH FLOW
Balance Sheet Decomposition
Achilles Therapeutics plc
| Current Assets | 146 M |
| Cash & Short-Term Investments | 132 M |
| Receivables | 10.4 M |
| Other Current Assets | 3.74 M |
| Non-Current Assets | 15.8 M |
| Long-Term Investments | 33 K |
| PP&E | 13.5 M |
| Other Non-Current Assets | 2.25 M |
| Current Liabilities | 17 M |
| Accounts Payable | 5.63 M |
| Short-Term Debt | 3.54 M |
| Other Current Liabilities | 7.83 M |
| Non-Current Liabilities | 2.09 M |
| Long-Term Debt | 1.08 M |
| Other Non-Current Liabilities | 1.02 M |
EFFICIENCY
Earnings Waterfall
Achilles Therapeutics plc
| Revenue | 0 |
| Cost Of Revenue | 4.73 M |
| Gross Profit | -4.73 M |
| Operating Expenses | 75.3 M |
| Operating Income | -75.3 M |
| Other Expenses | -5.32 M |
| Net Income | -69.9 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-48.93%
ROE
-43.15%
ROA
-53.23%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Achilles Therapeutics plc
| Net Income | -69.9 M |
| Depreciation & Amortization | 4.71 M |
| Capital Expenditures | -1.1 M |
| Stock-Based Compensation | 6.36 M |
| Change in Working Capital | 10.4 M |
| Others | 10.4 M |
| Free Cash Flow | -49.5 M |
Wall Street Analysts Price Targets
Achilles Therapeutics plc
Wall Street analysts predict an average 1-year price target for ACHL of $2 , with forecasts ranging from a low of $2 to a high of $2 .
ACHL Lowest Price Target
Wall Street Target
2 USD
90.48%
ACHL Average Price Target
Wall Street Target
2 USD
90.48%
ACHL Highest Price Target
Wall Street Target
2 USD
90.48%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Achilles Therapeutics plc
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –
globenewswire.com
- 2 days ago
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
Achilles Therapeutics Announces Strategic Update
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials.
globenewswire.com
- 1 month ago
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology –
globenewswire.com
- 3 months ago
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Research collaboration combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform
globenewswire.com
- 5 months ago
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice
globenewswire.com
- 6 months ago
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. “Just after the close of the first quarter, we shared the interim Phase I/IIa data from our ongoing CHIRON and THETIS TIL-based cNeT clinical trials which have given us important mechanistic learnings about the factors driving durable engraftment and immune evasion at an antigen level.
globenewswire.com
- 6 months ago
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights. “In 2023, we made important progress on the optimization of our VELOS™ manufacturing process with a significant improvement in cNeT doses delivered and are developing our understanding of the relationship between host conditioning and the engraftment of infused cNeT.
globenewswire.com
- 7 months ago
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma. The update includes data from 18 patients across CHIRON (n=12) and THETIS (n=6) dosed since the previous interim update in December 2022, with two CHIRON patients and one THETIS patient having received enhanced chemo-conditioning and IL-2 dosing aligned to standard tumor infiltrating lymphocyte (TIL) therapy (enhanced host conditioning) in a new Cohort C.
globenewswire.com
- 7 months ago
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:
globenewswire.com
- 9 months ago
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
globenewswire.com
- 11 months ago
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 – – Strong cash position of $140 million supports operations through 2025 – LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. “We are pleased with progress across the scientific field that continues to demonstrate the importance of neoantigens as the most attractive targets in solid-tumor oncology.
globenewswire.com
- 1 year ago
8. Profile Summary
Achilles Therapeutics plc ACHL
COUNTRY
GB
INDUSTRY
Biotechnology
MARKET CAP
$ 43.1 M
Dividend Yield
0.00%
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Contact
245 Hammersmith Road, London, W6 8PW
https://www.achillestx.com
IPO Date
March 31, 2021
Employees
204
Officers
Mr. Daniel Carey Cazel Hood
General Counsel & Company Secretary
Dr. Charles Swanton FMEDSCI, M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Tariq Ahmed
Executive Vice President of People
Mr. Lee M. Stern
Vice President of Investor Relations & External Communications
Mr. Edward Samuel
Executive Vice President of Technical Operations
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.
Founder & Member of Scientific Advisory Board
Julia Wilson
Head of Communications
Dr. Iraj Ali Ph.D.
Chief Executive Officer & Director
Dr. Sergio A. Quezada Ph.D.
Founder & Chief Scientific Officer
Mr. Robert Coutts
Chief Financial Officer